Overview
In recent years checkpoint inhibitors, particularly PD-1/PD-L1 inhibitors, have become an important component of the management of advanced NSCLC patients. In the future, these agents are expected to be used to treat patients with earlier stages of the disease and possibly in SCLC patients as well. These drugs have a unique adverse effect profile, many of which are immune-related. This planned webinar will discuss the adverse effects observed with these drugs, how one may monitor patients for these adverse events and guidelines for management of these adverse events.
After viewing this program, attendees will be able to:
- Describe the adverse events observed with PD-1/PD-L1 inhibitors.
- Demonstrate the adverse events observed with combinations involving PD-1/PD-L1 inhibitors.
- Recognize how to monitor for adverse events in patients receiving therapy with PD-1/PD-L1 inhibitors.
- Identify how to undertake the management of these adverse events.
Shirish M. Gadgeel, MD
Professor, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
For any inquiries, please contact meetings@iaslc.org.
After viewing this program, attendees will be able to:
- Describe the adverse events observed with PD-1/PD-L1 inhibitors.
- Demonstrate the adverse events observed with combinations involving PD-1/PD-L1 inhibitors.
- Recognize how to monitor for adverse events in patients receiving therapy with PD-1/PD-L1 inhibitors.
- Identify how to undertake the management of these adverse events.
Shirish M. Gadgeel, MD
Professor, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
For any inquiries, please contact meetings@iaslc.org.